



PB 113 of 2024

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 10)

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 98C(1) of the *National Health Act 1953*.

Dated 30 October 2024

NIKOLAI TSYGANOV
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division

Contents

1	Name	1
2	Commencement	1
3	Authority	1
4	Schedules	1
Schedule 1—Amendments		1
<i>National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019</i>		

1 Name

- (1) This instrument is the *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2024 (No. 10)*.
- (2) This instrument may also be cited as PB 113 of 2024.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. <i>The whole of this instrument</i>	<i>1 November 2024</i>	<i>1 November 2024</i>

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 98C(1) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)

[1] Schedule 3, after entry for Morphine in the form Tablet containing morphine sulfate pentahydrate 20 mg

insert:

Morphine	Tablet containing morphine sulfate pentahydrate 30 mg
----------	---

[2] Schedule 4, entries for Estradiol

substitute:

Estradiol	Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28
Estradiol	Transdermal patches 390 micrograms, 8
Estradiol	Transdermal patches 585 micrograms, 8
Estradiol	Transdermal patches 585 micrograms, 24 (S19A)
Estradiol	Transdermal patches 780 micrograms, 8
Estradiol	Transdermal patches 780 micrograms, 24 (S19A)
Estradiol	Transdermal patches 1.17 mg, 8
Estradiol	Transdermal patches 1.17 mg, 24 (S19A)
Estradiol	Transdermal patches 1.56 mg, 8
Estradiol	Transdermal patches 1.56 mg, 24 (S19A)
Estradiol	Transdermal patches 750 micrograms (as hemihydrate), 8
Estradiol	Transdermal patches 1.5 mg (as hemihydrate), 8
Estradiol	Transdermal patches 3 mg (as hemihydrate), 8

[3] Schedule 4, entry for Naloxone

omit:

Naloxone	Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2 (s19A)
----------	--

[4] Schedule 4, after entry for Timolol in the form Eye drops 5 mg (as maleate) per mL, 5mL

insert:

Timolol	Eye drops 5 mg (as maleate) per mL, 5 mL (S19A)
---------	---
